Answers are grounded in this paper and cite their sources.
Lazertinib is an oral, third-generation EGFR-TKI, which specifically targets the EGFR T790M mutation along with activating mutations Ex19del and L858R. More real-world data are needed to evaluate its efficacy and safety in treating locally advanced and metastatic non-small cell lung cancer (NSCLC) following prior EGFR TKI treatment.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: